Angelo S. Botter
Nessuna posizione attualmente
Storia della carriera di Angelo S. Botter
Precedenti posizioni note di Angelo S. Botter
Società | Posizione | Inizio | Fine |
---|---|---|---|
MEDEXUS PHARMACEUTICALS INC. | Direttore/Membro del Consiglio | 10/12/2013 | 02/06/2014 |
Advanced Viral Research Corp.
Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | Direttore/Membro del Consiglio | 31/05/2006 | 23/03/2009 |
Formazione di Angelo S. Botter
McGill University | Undergraduate Degree |
Statistiche
Distribuzione geografica
Canada | 3 |
Stati Uniti | 2 |
Posizioni
Director/Board Member | 2 |
Undergraduate Degree | 1 |
Settori
Health Technology | 3 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
MEDEXUS PHARMACEUTICALS INC. | Health Technology |
Aziende private | 1 |
---|---|
Advanced Viral Research Corp.
Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | Health Technology |
- Borsa valori
- Insiders
- Angelo S. Botter
- Esperienza